Home | Cardiovascular Business

The Independent Data Monitoring Committee recommended Bayer stop the trial due to the drug's poor performance compared to apixaban.

Read more about Bayer ends blood thinner trial early due to lack of efficacy

"Although the effectiveness of ADHD medications has been demonstrated ... concerns remain regarding their potential cardiovascular safety," one research explained.

Read more about ADHD medications associated with heightened CVD risk

Even patients with no symptoms may be at risk, according to new findings published in the Journal of Allergy and Clinical Immunology.

Read more about Sensitivity to dairy products, other foods linked to higher risk of death from heart disease

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System

Medtronic's PulseSelect Pulsed Field Ablation System. Image courtesy of Medtronic.

The company had good news to share about its highly anticipated PFA offering.

Read more about Medtronic gains 2 key approvals for its ablation portfolio

More and more AI algorithms are being trained to learn, think and act like a human physician. What does this mean for the future of cardiovascular imaging as time goes on?

Read more about Deep learning in cardiovascular imaging: 4 key takeaways for cardiologists

Hospital readmissions, ER visits and major complications were all less likely when TAVR patients used a smartphone app to assist with their recovery.

Read more about Smartphone app helps TAVR patients avoid major complications

Arineta Cardio Imaging, a healthcare company based in Israel, gained clearance from the U.S. Food and Drug Administration (FDA) for the deep learning image reconstruction (DLIR) technology used in its SpotLight cardiovascular CT scanners. Arineta Cardio Imaging cardiovascular CT scanners AI.

Image courtesy of Arineta Cardio Imaging.

The new technology, trained using more than 3 billion data points, was designed to reduce image noise and improve the overall quality of CT scans.

Read more about FDA clears AI-powered image reconstruction technology for cardiac CT scanners

Medtronic Symplicity Spyral renal denervation

This is the second time in a matter of weeks the FDA has approved an RDN system for uncontrolled hypertension. The SCAI issued a statement about this trend, calling it a “game-changer for both interventional cardiology and the treatment of hypertension."

Read more about FDA approves another renal denervation system for hypertension

A new gene-editing therapy has been tested on humans for the first time, resulting in a significant reduction in their low-density lipoprotein (LDL) cholesterol that could potentially last for decades. The study’s authors presented these early results at the AHA 2023 meeting.

While the therapy has been successfully tested on animals in the past, this study represents the first time it has been used on humans.

Read more about Gene-editing therapy lowers cholesterol in high-risk heart patients—one dose could potentially last decades

The Bern TAVI Registry looked at 2,500 TAVR patients to determine the level of prosthesis-patient mismatch (PPM) using transthoracic echocardiography (TTE), predicting PPM based one the size of the valve used, or using CT measurements of the aortic annulus to see which was method was most accurate at predicting PPM. Image courtesy of Tomii et al.

Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice.

Read more about Cardiologists may want to rethink how they track prosthesis-patient mismatch after TAVR